In conclusion, given the negative impact of DM and obesity on gonadal function in humans, the use of GLP1‐RAs could play an important role in the management of hypotestosteronemia and infertility in patients with these dysmetabolic disorders. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.